Application of Ultraviolet Blood Irradiation for Treatment of HIV and Other Bloodborne Viruses
This paper describes an innovative method of inactivating blood-borne viruses using ultraviolet blood irradiation called UBI therapy. This process has shown impressive clinical results in treating hepatitis, HIV, and other currently untreatable viruses. The background, theory, and method of using UBI therapy is presented in this paper. This method offers a potential break-through in the treatment of viral diseases and bacteria, and is nontoxic, uses no drugs, and even has FDA certification, and thus is available now for use.
Ultraviolet blood irradiation first evolved in the early 1930s as a means to treat persons afflicted with the poliovirus which was causing considerable anguish and fear similar to the advent of the HIV in the 1980s and continuing. Then in the 1950s the Salk vaccine wiped out polio in the U.S. and, as a result of this fact and other reasons, this process fell in disuse until recent years. This process has now been resurrected by the Foundation for Blood Irradiation (FFBI) which had been originally founded in the 1940s by the developers of this process, most of whom are now deceased, who left this to the next generation of researchers to continue. Much credit for the early development of this technology goes to E.K. Knott of Seattle, Washington; Louis Ripley of Danbury, Connecticut; and Dr. T. Lewis of Pittsburgh, Pennsylvania.
Ultraviolet blood irradiation therapy (UBIT), or intravenous ultraviolet, raises the resistance of the host and is therefore able to control many disease processes. A fundamental effect of ultraviolet blood irradiation is to “energize” the biochemical and physiological defenses of the body by the introduction of ultraviolet energy into the bloodstream that may, in part, be effective by producing small amounts of ozone from the oxygen circulating in the blood. The efficacy of this method is attested to by the remarkable and consistent recovery of patients with a wide variety of diseases, apparently unrelated etiologically. In addition, it may be stated that UBI has never caused any adverse side effects nor has it ever worsened any disease in any patient, regardless of age group, race or sex and regardless of the number of blood irradiation treatments administered. Furthermore, there have not been any complications related to UBIT during long-term follow-up.
An average of 3.28 treatments per patient were administered in this series. Laboratory studies were employed to confirm clinical improvement, which occurred on an average of 19.2 days after institution of blood irradiation therapy. Sixty percent of the patients were considered clinically recovered and able to return to their occupation in two weeks or less.The older UBIT units have been updated and are now available and FDA certified for use in the U.S. These units are being further evaluated for improvements; this is being carried out under a CRADA (Cooperative Research and Development Agreement) with the Lawrence Livermore National Laboratories of Berkeley, California. Steps are now being taken to arrange research protocols at several major university medical research centers on both the East and West coasts of the U.S. Focus will be on treatment of HIV, hepatitis, malaria, and those viruses immune to current antibiotics.
Researchers in Russia have used this process to treat HIV with impressive results. A copy of this report will be sent to those who request it for the cost of photocopying. This report provides specific details, clinical results, and improvements noted in the HIV-infected patients in terms of CD4 T cells, leucocytes, etc. With respect to treating HIV-positive persons, our clinicians also administer the following natural products: ESSIAC, VENUREX (formerly Carnivora), and a Czechoslovak produced product called Imuregen. Each of these are being evaluated at NCI and NIAID per agreements we hold there.
Ultraviolet blood irradiation therapy (UBIT) is currently FDA approved (and the treatment of choice) for cutaneous T-cell lymphoma (CTCL) (Taylor & Gasparro, 1992). Using a technique based on extensive historical experience with PUVA therapy in dermatology, Edelson and his group at Yale have developed a sophisticated UBIT method involving pretreatment with psolaren, extracorporeal leukopheresis, UV-A irradiation of the white blood cell fraction, and reinfusion (Edelson, 1987). This process has been given the name “photopheresis.”
Photopheresis is currently undergoing clinical trials at centers around the country for the treatment of systemic sclerosis, multiple sclerosis, rheumatoid arthritis, autoimmune insulin-dependent diabetes, systemic lupus erythematosis, myasthenia gravis, graft versus host disease, pemphigus vulgaris, and HIV associated disease (Edelson, 1991; Bisaccia et al. 1990). The major drawbacks to photopheresis are that the technique is cumbersome and costly; a single treatment occupies patient and skilled technician for upwards of five hours.
Historically, the Knott technique of UBIT (Knott, 1948) was applied extensively and with excellent results during the 1930s, 40s, and 50s for the treatment of a wide variety of conditions. There are published reports on its use in bacterial diseases, including septicemias, pneumonias, peritonitis, wound infections; viral infections including acute and chronic hepatitis, atypical pneumonias, poliomyelitis, encephalitis, mumps, measles, mononucleosis, and herpes; circulatory conditions including thrombophlebitis, peripheral vascular arterial disease, and diabetic ulcer; overwhelming toxemias, non-healing wounds and delayed union of fractures, rheumatoid arthritis, and a number of others (Barger & Knott, 1950). Schwartz and his colleagues in Chicago concluded a critical examination of the Knott technique (Schwartz et al. 1952) by saying “a longer and more extensive program of study is warranted before in vivo blood irradiation of blood can be finally either accepted or rejected.” However,
before such further examination could be undertaken, several other factors intervened. Principal among these was the development of antibiotics whose early successes made it appear that soon all infectious diseases would be conquered by chemistry. In addition, however, after World War II, there had been great interest in the possibilities of employing UV
light to sterilize blood and blood products for transfusion (Oliphant & Hollaender, 1946; Wolf et al. 1947; Blanchard et al. 1948). When this effort failed after premature approval in 1949 and subsequent commercialization, the whole field of ultraviolet blood irradiation was quickly forgotten (Murray et al. 1955).
UBIT virtually disappeared from the early 1980s when the Soviets began referring to the published work of Knott and his colleagues. In the current listings of world medical literature at the National Library of Medicine on UBIT (excluding photopheresis) there are over 100 articles, and all of these are in the Soviet literature. Like Knott, it appears that the Soviets
have applied UBIT to a wide variety of conditions, but only over the past two decades (Arutiunov, 1988).
We propose to reexamine the Knott technique with the advantage of vastly improved technical and medical tools. Viral illnesses, given their comparative resistance to chemotherapeutic
control, have emerged over the past several decades as a major challenge for medicine. In addition, immune system dysfunctions are increasingly recognized as playing a major “host actor” role in many disease processes, including cancer. Given the range of potential applications of UBIT, a program of study is warranted.